Mee Paul, Fielding Katherine L, Charalambous Salome, Churchyard Gavin J, Grant Alison D
London School of Hygiene and Tropical Medicine, London, UK.
AIDS. 2008 Oct 1;22(15):1971-7. doi: 10.1097/QAD.0b013e32830e4cd8.
To assess the performance of WHO clinical and CD4 cell count criteria for antiretroviral treatment (ART) failure among HIV-infected adults in a workplace HIV care programme in South Africa.
Cohort study.
We included initially ART-naive participants who remained on first-line therapy and had an evaluable HIV viral load result at the 12-month visit. WHO-defined clinical and CD4 cell count criteria for ART failure were compared against a gold standard of virological failure.
Among 324 individuals (97.5% men, median age 40.2, median starting CD4 cell count and viral load 154 cells/mul and 47,503 copies/ml, respectively), 33 (10.2%) had definite or probable virological failure at 12 months, compared with 19 (6.0%) and 40 (12.5%) with WHO-defined CD4 and clinical failure, respectively. CD4 criteria had a sensitivity of 21.2% and a specificity of 95.8% in detecting virological failure, and clinical criteria had sensitivity of 15.2% and specificity of 88.1%. The positive predictive value of CD4 and clinical criteria in detecting virological failure were 36.8 and 12.8%, respectively. Exclusion of weight loss or tuberculosis failed to improve the performance of clinical criteria.
WHO clinical and CD4 criteria have poor sensitivity and specificity in detecting virological failure. The low specificities and positive predictive values mean that individuals with adequate virological suppression risk being incorrectly classified as having treatment failure and unnecessarily switched to second-line therapy. Virological failure should be confirmed before switching to second-line therapy.
评估世界卫生组织(WHO)关于抗逆转录病毒治疗(ART)失败的临床及CD4细胞计数标准,用于南非一项职场HIV护理项目中HIV感染成人的情况。
队列研究。
我们纳入了最初未接受过ART治疗且持续接受一线治疗,并在12个月随访时有可评估HIV病毒载量结果的参与者。将WHO定义的ART失败的临床及CD4细胞计数标准与病毒学失败的金标准进行比较。
在324名个体中(97.5%为男性,中位年龄40.2岁,起始CD4细胞计数和病毒载量的中位数分别为154个/微升和47,503拷贝/毫升),33人(10.2%)在12个月时出现明确或可能的病毒学失败,而根据WHO定义的CD4和临床失败标准分别为19人(6.0%)和40人(12.5%)。CD4标准在检测病毒学失败方面的敏感性为21.2%,特异性为95.8%;临床标准的敏感性为15.2%,特异性为88.1%。CD4和临床标准在检测病毒学失败方面的阳性预测值分别为36.8%和12.8%。排除体重减轻或结核病因素未能改善临床标准的性能。
WHO的临床及CD4标准在检测病毒学失败方面敏感性和特异性较差。低特异性和阳性预测值意味着病毒学抑制良好的个体有被错误分类为治疗失败并被不必要地转换为二线治疗的风险。在转换为二线治疗之前应确认病毒学失败。